<?xml version="1.0" encoding="UTF-8"?>
<p>Data on patients' characteristics, treatment, outcome and toxicity were recorded on case record forms (CRFs). Information on participation in clinical trials, type of hospital (county/rural, regional or university) where the main body of treatment was given, where the decision on treatment was taken, geographical region, and whether choice of first-line therapy was compliant to the actual Swedish national CLL guidelines
 <sup>
  <xref rid="b3-1040797" ref-type="bibr">3</xref>
 </sup> was also recorded. Furthermore, concomitant medication with acetylsalicylic acid (ASA) or statins were recorded since these drugs appear to induce apoptosis on CLL cells
 <sup>
  <xref rid="b25-1040797" ref-type="bibr">25</xref>,
  <xref rid="b26-1040797" ref-type="bibr">26</xref>
 </sup> and may improve outcome in FCR-treated CLL.
 <sup>
  <xref rid="b27-1040797" ref-type="bibr">27</xref>
 </sup> Data were incorporated in a specially developed version of the Information Network for Cancer Care (INCA) database and systematically cross-checked and validated for accuracy. Treatment response was evaluated according to the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria.
 <sup>
  <xref rid="b28-1040797" ref-type="bibr">28</xref>
 </sup> Major infections (grade III-V) and other serious adverse events (SAE) according to the NCI CTCAE 3.0 were recorded. Richter transformation (RT) and secondary tumors were also recorded. The Swedish Cause of Death Registry was used to validate records of death.
 <sup>
  <xref rid="b29-1040797" ref-type="bibr">29</xref>
 </sup>
</p>
